Cynthia Chmielewski | CureTalks
Cynthia attended Rutgers University graduating with degrees in Psychology and Education. Upon graduation she secured her first teaching position and immediately fell in love with her chosen profession. Cynthia continued teaching for 28 years. Now retired, Cynthia, a myeloma survivor, is using her passion for education to teach a new group of "students" - myeloma patients and their caregivers. She is on the advisory boards of the Patient Empowerment Network, the Myeloma Crowd and the Philadelphia Multiple Myeloma Networking Group. Using social media to educate is her passion. Cynthia educates and advocates by tweeting at @MyelomaTeacher and sharing myeloma resources, educational opportunities and clinical trial information on her MyelomaTeacher Facebook page. Ms. Chmielewski is the co-founder of the #MMSM TweetChat and is also a regular panelist on CureTalks Podcast. Cynthia was an invited panelist and presented posters on using social media in hematology at the annual meetings of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR) and the European Bone Marrow Transplant (EBMT). More recently Cynthia joined the Patient Engagement team at Patient Power. Additionally, she consults on educational projects sponsored by the Myeloma Crowd. She enjoys serving as a voting member on the IRB at the University of Pennsylvania, a peer reviewer for the NCI’s DEA grants program and a patient advocate on the Myeloma Steering Committee of the National Cancer Institute (NCI) and ACCRU. Cynthia has also participated in the Department of Defense’s CMCRP grant reviews.
Related Talks
Understanding iSTOPMM: Iceland Screens, Treats, or Prevents Multiple Myeloma with Dr. Sigurour Yngvi Kristinsson
iStopMM initiative may be one of most important events in modern day myeloma care. As part of the iStopMM study, 140,000 Icelanders over…
History and Future Initiatives for High Risk Smoldering Myeloma Cure
For this second talk in our high risk smoldering myeloma series, we have Prof. Jesus San Miguel from University of Navarra, Spain discuss…
Understanding ASCENT Clinical Trial for High Risk Smoldering Myeloma Patients
This is the first of a 3 part series of talk on high risk smoldering myeloma and its treatments. Smoldering multiple myeloma (SMM)…
The New Optimism of Combination Therapies in Multiple Myeloma Treatment.
Clinical trials of new combination therapies are showing promising results and can be a game changer in myeloma treatment - Combining standard drugs…
Everything you need to know about Daratumumab and Multiple Myeloma
FDA recently approved daratumumab (Darzalex) to treat patients with multiple myeloma who have received atleast three prior treatments. Daratumumab is the first monoclonal…